DK1048726T3 - Modificeret faktor VIII-cDNA - Google Patents

Modificeret faktor VIII-cDNA

Info

Publication number
DK1048726T3
DK1048726T3 DK00104677T DK00104677T DK1048726T3 DK 1048726 T3 DK1048726 T3 DK 1048726T3 DK 00104677 T DK00104677 T DK 00104677T DK 00104677 T DK00104677 T DK 00104677T DK 1048726 T3 DK1048726 T3 DK 1048726T3
Authority
DK
Denmark
Prior art keywords
factor viii
modified factor
viii cdna
blood coagulation
expression
Prior art date
Application number
DK00104677T
Other languages
English (en)
Inventor
Claude Dr Negrier
Jean Luc Plantier
Original Assignee
Negrier Claude
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99104050A external-priority patent/EP1038959A1/en
Application filed by Negrier Claude filed Critical Negrier Claude
Application granted granted Critical
Publication of DK1048726T3 publication Critical patent/DK1048726T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
DK00104677T 1999-03-17 2000-03-03 Modificeret faktor VIII-cDNA DK1048726T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99104050A EP1038959A1 (en) 1999-03-17 1999-03-17 Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
EP99107397A EP1048736A1 (en) 1999-04-27 1999-04-27 DNA-construct for the tissue specific expression of a blood coagulation factor

Publications (1)

Publication Number Publication Date
DK1048726T3 true DK1048726T3 (da) 2006-11-20

Family

ID=8237961

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00104677T DK1048726T3 (da) 1999-03-17 2000-03-03 Modificeret faktor VIII-cDNA

Country Status (11)

Country Link
US (1) US6884616B1 (da)
EP (2) EP1048736A1 (da)
JP (1) JP4373578B2 (da)
KR (1) KR100681719B1 (da)
AT (1) ATE339510T1 (da)
AU (1) AU779437B2 (da)
CA (1) CA2304376C (da)
DE (1) DE60030621T2 (da)
DK (1) DK1048726T3 (da)
ES (1) ES2270758T3 (da)
PT (1) PT1048726E (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE489105T1 (de) 2004-03-19 2010-12-15 Baxter Int Faktor ixa zur behandlung von blutungsstörungen
EP2205249B1 (en) 2007-09-28 2018-11-07 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
CN102112144A (zh) * 2008-05-16 2011-06-29 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
DK2912186T3 (da) * 2012-10-24 2021-02-22 Platelet Targeted Therapeutics Llc Behandling rettet mod blodplader
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678282B1 (fr) * 1991-06-28 1994-08-26 Commissariat Energie Atomique Sequences amplificateur et silenceur isolees du promoteur de la gpiib, et leurs applications.
JPH08511423A (ja) * 1993-06-10 1996-12-03 ジェネティック セラピー，インコーポレイテッド 血友病治療のためのアデノウイルスベクター
US6066778A (en) * 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
FR2763959A1 (fr) 1997-06-02 1998-12-04 Transgene Sa Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage

Also Published As

Publication number Publication date
EP1048735A1 (en) 2000-11-02
KR20010020795A (ko) 2001-03-15
ES2270758T3 (es) 2007-04-16
DE60030621T2 (de) 2007-09-27
JP2000333687A (ja) 2000-12-05
JP4373578B2 (ja) 2009-11-25
AU779437B2 (en) 2005-01-27
ATE339510T1 (de) 2006-10-15
EP1048736A1 (en) 2000-11-02
US6884616B1 (en) 2005-04-26
CA2304376A1 (en) 2000-10-29
CA2304376C (en) 2010-06-01
PT1048726E (pt) 2006-12-29
KR100681719B1 (ko) 2007-02-15
EP1048735B1 (en) 2006-09-13
DE60030621D1 (de) 2006-10-26
AU3019500A (en) 2000-11-02

Similar Documents

Publication Publication Date Title
NZ509633A (en) A recombinant chimeric PEG-uricase with a long circulatory life and reduced immunogenicity
ATE199938T1 (de) Adenovirus-aav zwittervirus sowieverfahrungen zur verwendung davon
EE04817B1 (et) Kudede regeneratsiooni modulaatorid
DE605477T1 (de) Gasförmige ultraschallkontrastmittel und verfahren zur auswahl von gasen für die verwendung als ultraschallkontrastmittel.
DE69736068D1 (de) Faktor viii vom schwein und hybriden
EA200600746A1 (ru) Конструкции нуклеиновых кислот
AU1094892A (en) Improved activation of recombinant proteins
FR2832716B1 (fr) Proteine de fusion ayant augmente l'activite in vivo de l'erythroproietine
BR0213298A (pt) formulações com alta concentração de proteìna e processo de fabricação
DK1048726T3 (da) Modificeret faktor VIII-cDNA
DE60207490D1 (de) Verfahren zur Herstellung von (Meth)Acrylsäureanhydrid
ATE339878T1 (de) Myc-bindende zinkfinger-proteine, ihre herstellung und ihre verwendung
DE50208306D1 (de) Verfahren zur Herstellung von nicht-proteinogenen L-Aminosäuren
DE69723769D1 (de) Direkteinspritzung von Sauerstoff in der Herstellung von Salpetersäure
ATE431363T1 (de) Modifizierte faktor viii cdna und ihre verwendung zur produktion von faktor viii
ATE277170T1 (de) Stereoselektive transaminase, deren kodierende gen und deren verwendungen
ATE512217T1 (de) 5-substituerte hydantoin racemase, dafür kodierende dna, und verfahren zur herstellung optisch aktiver aminosäure
DK1205542T3 (da) L-aminosyre-oxidase fra Rhodococcus arter
DE69934415D1 (de) Neuartiges collectin
DE60238810D1 (de) Rekombinante D-Hydantoin Hydrolasen und N-Carbamyl-Aminosäure Amid Hydrolasen, dafür kodierende DNA; deren Verwendung zur Herstellung von D-Aminosäuren
DE69533626D1 (de) Tioredioxine h aus zwig und hart-weizen und ähnliche proteine, diese kodierende dna-fragmente und verfahren zu ihrer herstellung
ATE286509T1 (de) Interferon alpha/beta bindendes protein, seine herstellung und anwendung
ATE162853T1 (de) Menschlicher rekombinanter plazentaler ribonuklease-inhibitor und verfahren zur herstellung
DE69534738D1 (de) Leukocyten-aktivierender Faktor
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same